

WORLD BIOSIMILARS CONFERENCE

Annual Conference on NEPHROLOGY AND UROLOGY

August 20-21, 2018
Chicago, USA



Ronald P Dudek

Lentigen Technology Inc., USA

The Adapter CAR™: A novel universal chimeric antigen receptor (CAR) that can turn a biosimilar antibody into a CAR T cell

The workshop will start with a review of the chimeric antigen receptor (CAR) and CAR engineered T cells, and segue into an introduction of a novel universal CAR, the Adapter CAR™, that can turn any antibody into a CAR T cell. Most of the workshop will be focused on how to manufacture CAR T cells, including two videos on a novel automated CAR T cell manufacturing solution, the Miltenyi Biotec CliniMACS Prodigy system.

Biography


Ronald P Dudek is a CAR T cell entrepreneur. His latest company, Living Pharma, Inc., was acquired by Lentigen Technology, Inc., where he is employed as Director of Technology Development, Adapter CAR Program Manager. Mr. Dudek has a B.S., Biological Science degree, summa cum laude, from Fordham University, NY, NY and an MBA, Marketing and Finance, from U.C. Berkeley, Berkeley, CA.

ron.dudek@lentigen.com

The Adapter CAR™ Universal CAR



- Adapter CAR T cells seek out and kill tagged antibody bound cancer cells.
- Single or multi-targeting possible.
- Antibodies act as built-in off-switch.
- Antibody dosing adds an additional level of control of therapy.



Notes: